ArticleMedicine2026
A cross-sectional assessment of the diagnostic value of serum ceruloplasmin for Wilson's disease in children.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wilson's disease (WD) is a rare autosomal recessive disorder of copper metabolism requiring early diagnosis to prevent severe hepatic and neurological damage, particularly in children, where diagnostic challenges are pronounced. Serum ceruloplasmin (CPN) is a critical biochemical marker, yet its diagnostic accuracy and optimal cutoff value in pediatric populations need further evaluation in specific regional contexts. This study evaluates the diagnostic performance of serum CPN in diagnosing WD among children at Damascus University Children's Hospital and determines an optimal diagnostic cutoff value for this population. A bidirectional cross-sectional study was conducted from January 2019 to December 2022 at Damascus University Children's Hospital, including 80 children diagnosed with WD (case group) and 80 children with hepatic symptoms but without WD (control group), all under 13 years. Serum CPN was measured using immunoturbidimetry. Data on demographics, clinical presentations, Kayser-Fleischer rings, CPN levels, and 24-hour urinary copper were collected. Statistical analyses included t-tests, receiver operating characteristic analysis, and multiple linear regression (Statistical Package for Social Sciences). Ethical approval and informed consent were obtained. Mean age in the WD group was 119.15 ± 30.47 months (57.5% female). Serum CPN was significantly lower in WD (9.8 ± 3.2 mg/dL) versus controls (27.6 ± 10.4 mg/dL, P < .001). Receiver operating characteristic analysis showed high diagnostic accuracy (AUC = 0.967, 95% CI: 0.945-0.988), with an optimal CPN cutoff of 15 mg/dL (sensitivity 93.8%, specificity 85.0%). Regression identified age, female sex, neurological symptoms, Kayser-Fleischer rings, and urinary copper as predictors of lower CPN. Serum CPN is a highly accurate diagnostic marker for pediatric WD, with a 15 mg/dL cutoff optimizing sensitivity and specificity. Interpretation should consider age, sex, and clinical features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.